I reported previously (Jan 2015) on the promising trials for the Fabry disease treatment PRX-102 from Israel’s Protalix. PRX-102 is currently in Phase III trials and has just been granted fast-track status by the US FDA. Fabry disease damages the kidneys and heart and has no cure.
https://www.globes.co.il/en/article-fda-fast-tracks-protalixs-fabry-disease-drug-1001221935